participant.ui.study.eligibility-status-cta.not-recruiting
common.study.topics.clinical

Efficacy of Large B-Cell Lymphoma Treatments

common.study.values.description

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Polatuzumab Vedotin

Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.

Drug - Rituximab

Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

Drug - Cyclophosphamide

Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

Drug - Doxorubicin

Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

Drug - Vincristine

Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

Drug - Vincristine Placebo

Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.

Drug - Prednisone

Prednisone PO will be administered as per the schedule specified in the respective arm.

Drug - Polatuzumab vedotin Placebo

Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

common.study.values.clinical-trial-id

NCT03274492

participant.views.study.view.id

0dNwLe